Tag Archives: Carmot

Lilly’s Tempo Smart Button Receives 510(k) Clearance; EASD 2022 Key Press Releases (Sept 21)

On the third day of EASD 2022, three key press releases were observed from Zealand, Carmot Therapeutics, and Abbott. Separately, Lilly’s Tempo Smart Button received FDA 510(k) clearance on September 16, 2022 (view FDA website), although Lilly has not issued a press release. Below FENIX provides insights and context for the respective announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

New Dual GLP-1/GIP RA from Carmot Receives IND; Lilly ESG Strategy Highlights; Pfizer Q1 ’21 Earnings Update

Three diabetes-related news items have been observed: Carmot Therapeutics announced it has received IND clearance from FDA for its dual GLP-1/GIP RA, CT-868, in overweight and obese adults with T2DM; Lilly hosted an investor call outlining its commitments for the company’s newly updated environmental, social, and governance (ESG) strategy; and Pfizer hosted its Q1 ’21 earnings call but did not mention its metabolic pipeline during the webcast. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here